Print this page
-
Therapy and Outcome Prediction using Urothelial Carcinoma orgANoids (TOUCAN)
Protocol: 002425Principal Investigator:
- Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
Research on the Epidemiology of Prostate Cancer and Environmental Levels (REPEL)
Protocol: 002438Principal Investigator:
- Hari Iyer
Applicable Disease Sites: Prostate -
Quality of Life Outcomes of Transurethral Resection of Bladder Tumor and Intravesical Therapy in Non-Muscle Invasive Bladder Cancer
Protocol: 002450Principal Investigator:
- Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
- Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue -
Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy.
Protocol: 082003Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Prostate -
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer.
Protocol: 082105Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation.
Protocol: 082201Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Prostate -
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy.
Protocol: 082210Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study).
Protocol: 082212Principal Investigator:
- Thomas Jang
Applicable Disease Sites: Other Male Genital -
A Phase 3, Randomized, Open-Label Study of MK-5684 (004) Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA).
Protocol: 082307Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer.
Protocol: 082401Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Urinary Bladder -
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment.
Protocol: 082403Principal Investigator:
- Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
A Randomized Trial of High-Risk Metachronous OligometastatIc Prostate Cancer with High-Risk Mutations Treated with Metastasis Directed Therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS).
Protocol: 082405Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Prostate -
A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684 Based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Protocol: 082408Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma.
Protocol: 082409Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
Translational Research on Integrated Predictive Liquid and Excretory biomarkers in Urothelial Carcinoma (TRIPLE-UC)
Protocol: 082412Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder
- 1
- 2